Iterum Therapeutics ITRMF

Iterum Therapeutics plc is a pharmaceutical company dedicated to maximizing the commercial potential of ORLYNVAH™, the first oral branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. The company has developed sulopenem in both IV and oral formulations, with oral sulopenem (sulopenem etzadroxil-probenecid) marketed as ORLYNVAH™. This product received FDA approval on October 25, 2024, for treating uncomplicated urinary tract infections in adult women caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis when limited or no alternative oral antibacterial treatment options exist. Iterum Therapeutics plc exclusively licenses key patents from Pfizer and owns additional intellectual property related to its sulopenem formulations and uses.

Iterum Therapeutics plc does not currently generate revenue from product sales as it prepares for the commercial launch of ORLYNVAH™ following its October 2024 FDA approval. The company plans to generate revenue primarily through the sale of ORLYNVAH™ for the treatment of uncomplicated urinary tract infections. Revenue strategies under consideration include direct commercialization in the United States with a targeted sales force, partnership with a commercial entity, or pursuing strategic alternatives such as licensing or sale of its sulopenem rights. The company may also seek to expand its product pipeline through in-licensing or acquisition of additional anti-infective candidates and pursue development of sulopenem for other indications including complicated urinary tract infections, community-acquired bacterial pneumonia, and bacterial prostatitis.

Iterum Therapeutics plc operates in the antibiotic market with a specific focus on overcoming antibacterial resistance in urinary and intra-abdominal infections. The company's sulopenem program addresses a critical unmet need as resistance to first-line antibiotics like fluoroquinolones and trimethoprim-sulfamethoxazole exceeds 20% nationally for Escherichia coli, the most common cause of UTIs. ORLYNVAH™ differentiates itself through its targeted spectrum of activity against key uropathogens (E. coli, K. pneumoniae, P. mirabilis, and B. fragilis) while avoiding activity against organisms like Pseudomonas aeruginosa that could drive carbapenem resistance. The product demonstrates activity against multidrug-resistant pathogens and has a favorable safety profile observed across Phase 3 trials, with discontinuation rates below 1% in the recently completed REASSURE trial. Competitors include established oral antibiotics (ciprofloxacin, nitrofurantoin, TMP-SMX) and newer agents in development, as well as IV antibiotics that require hospital administration.

Iterum Therapeutics plc targets adult women suffering from uncomplicated urinary tract infections (uUTIs) caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis, which collectively represent over 95% of uUTI cases. The company focuses specifically on patients with limited oral antibiotic options due to quinolone resistance or other resistance patterns, representing approximately 30% of all uUTIs in the United States. Based on market research, approximately 40 million total uUTI prescriptions occur annually in the United States, with about 26 million written for patients at elevated risk for treatment failure due to factors like recurrent infections, elderly age, comorbidities (e.g., diabetes), immunosuppression, recent hospitalization, prior antibiotic failure, or long-term care residence. The company also identifies opportunities in more serious infections, noting approximately 3.6 million patients annually require antibiotic therapy for complicated UTIs and 350,000 for complicated intra-abdominal infections in the United States.